Bridgewater Associates’s 10x Genomics TXG Stock Holding History

Bridgewater Associates’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$513K	Sell	13,375 -21,726	-62%	-$569K	﹤0.01%	919
2026 Q1	$745K	Sell	35,101 -142,633	-80%	-$2.85M	﹤0.01%	834
2025 Q4	$2.9M	Buy	+177,734	New	+$2.68M	0.01%	681
2023 Q1	–	Sell	-13,044	Closed	-$475K	–	899
2022 Q4	$475K	Buy	+13,044	New	+$426K	﹤0.01%	727
2022 Q3	–	Sell	-8,676	Closed	-$393K	–	1018
2022 Q2	$393K	Buy	8,676 +2,494	+40%	+$129K	﹤0.01%	923
2022 Q1	$470K	Buy	+6,182	New	+$541K	﹤0.01%	896
2021 Q4	–	Sell	-1,988	Closed	-$289K	–	806
2021 Q3	$289K	Buy	+1,988	New	+$341K	﹤0.01%	638

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bridgewater Associates's TXG Position: Q2 2026 in Review

Bridgewater Associates reduced its 10x Genomics (TXG) stake by 62% in Q2 2026, selling an estimated $569K and leaving 13,375 shares worth $513K. The position accounts for ﹤0.01% of the portfolio, ranked #919.

Bridgewater Associates first reported a position in TXG in Q3 2021 and has held it in 7 quarters since. The position peaked at $2.9M in Q4 2025. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Bridgewater Associates held 13,375 shares of 10x Genomics worth $513K as of Q2 2026.
Bridgewater Associates sold 21,726 10x Genomics shares in Q2 2026, an estimated $569K.
10x Genomics made up ﹤0.01% of Bridgewater Associates's portfolio in Q2 2026, its #919 holding.
Bridgewater Associates first reported a position in 10x Genomics in Q3 2021 and has held it in 7 quarters since.
Bridgewater Associates's 10x Genomics position peaked at $2.9M in Q4 2025.
390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.